Abstract:Immune thrombocytopenia is a fairly common clinical problem that may be due to either autoantibodies (such as chronic immune thrombocytopenia purpura [ITP]), alloantibodies (such as post-transfusion purpura or neonatal purpura), or drug-dependent antibodies. Chronic ITP is the most common form of immune thrombocytopenia and is due to platelet sensitization by circulating antiplatelet autoantibodies, which results in platelet destruction by the reticuloendothelial system. Immune thrombocytopenia similar to that in chronic ITP can be seen with a variety of diseases, particularly collagen vascular disorders (such as systemic lupus erythematosus) and lymphoproliferative disorders. Harrington et al provided the first evidence for a circulating antiplatelet factor in chronic ITP when they noted that the infusion of blood or plasma from ITP patients into normal recipients resulted in the rapid onset of thrombocytopenia. Subsequent in vivo studies by Shulman et al confirmed these findings and established that the antiplatelet factor also reacted with autologous platelets and that its effect was dose dependent and it could be removed by adsorption of the plasma with platelets. When serum fractions were studied, the antiplatelet factor was in the immunoglobulin G (IgG)-rich fraction. Following these important in vivo studies, multiple attempts were made to develop a useful in vitro assay. Initial methods involved platelet factor 3 release, serotonin release, platelet aggregation, and complement activation. However, none of these were sufficiently sensitive or specific to be clinically useful in the evaluation of autoantibodies, although some proved valuable in studying alloantibodies. In 1971, McMillan et al reported that incubation of normal platelets with plasma from some chronic ITP patients resulted in an increase in platelet-associated IgG (PAIgG). In 1975, Dickson et al measured PAIgG on ITP platelets and reported elevated levels in about 90% of patients. Subsequent studies from a multitude of groups confirmed that about 90% of ITP patients had elevated PAIgG values and about one-half had plasma antibodies that would bind to normal platelets. Following the initial enthusiasm associated with the PAIgG studies, it became apparent by the early 1980s that, although PAIgG was increased in patients with immune thrombocytopenia, it was also elevated in many patients with nonimmune thrombocytopenia and therefore was not specific for autoantibody.' Subsequent studies have shown that most of the PAIgG is found in the platelet alpha granules and probably reflects platelet age and size rather than antiplatelet antibody (reviewed by Sinha and Kelton and George). Van Leeuwen et al provided the first objective evidence for autoantibodies in chronic ITP. They reported that antibody eluates from the platelets of most ITP patients bound to normal platelets but not to thrombasthenic platelets. Because platelets from thrombasthenic patients are deficient in platelet glycoproteins (GP) IIb and IIIa, they postulated that these patients had autoantibodies to one of these glycoproteins. Subsequent studies using a variety of antigen-specific methods have provided direct evidence for this hypothesis. Woods et al showed binding of plasma autoantibodies from ITP patients to glycoproteins attached to microtiter wells with monoclonal antibodies and confirmed these observations using a radioimmunoprecipitation test. Positive results against either GPIIb/IIIa or GPIb/IX were noted in about 15% of chronic ITP patients. This percentage was much less than that observed by the indirect studies of van Leeuwen et al. Beardsley et al were the first to demonstrate autoantibody binding to a single glycoprotein. Using an immunoblot assay, they showed that plasma autoantibodFrom the Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California. This study was supported by grants HL37945 and RR00833 from the U.S. Public Health Service. Reprint requests: Dr. McMillan, Division of Hematology/ Oncology, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, CA 92037.

[Housing Project 'Living Independently with Intensive Support (WmI)': The Scientific Evaluation].

Analyze of Factors and Prognosis of Eyes Lost to Follow-Up in Retinal Vein Occlusive Disease Patients Receiving Anti-Vascular Endothelial Growth Factor Therapy

Cerebrospinal fluid drainage duration after thoracoabdominal aortic aneurysm repair.

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 1

Comments to: Aristotle Score for ‘‘Hybrid Procedure’’

A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 2.

Impact of anti-VEGF treatment-free interval during the first year on 5-year outcomes in eyes with branch retinal vein occlusion

Branch retinal vein occlusion treated with anti VEGF, to switch or not to switch? Long term follow-up

Clinical Role of Antiplatelet Antibody Assays

Relationship between Recurrence of Macular Edema Due to Branch Retinal Vein Occlusion and Changes in Choroidal Thickness

Patient Experience Survey Of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion

Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion

Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes

Evaluation and reduction of aberrations in distributed-index lenses: a review.

Subretinal fluid in macular edema secondary to branch retinal vein occlusion

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept—A Prospective Study

Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?

Visual and anatomical outcomes following intravitreal treatment of macular oedema secondary to retinal vein occlusion